North America Epilepsy Drugs Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology                  
2    Executive Summary
3    North America  Epilepsy Drugs Market Overview 
    3.1    North America Epilepsy Drugs Market Historical Value (2017-2023) 
    3.2    North America Epilepsy Drugs Market Forecast Value (2024-2032)
4    North America  Epilepsy Drugs Market Landscape*
    4.1    North America Epilepsy Drugs Market: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    North America Epilepsy Drugs Market: Product Landscape
        4.2.1    Analysis by Seizure Type    
        4.2.2    Analysis by Drug Generation
5    North  America Epilepsy Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Analysis
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    North America Epilepsy Drugs Market Segmentation (2017-2032)
    6.1    North America Epilepsy Drugs Market (2017-2032) by Seizure Type
        6.1.1    Market Overview
        6.1.2    Focal Seizures
        6.1.3    Generalized Seizures
        6.1.4    Non-epileptic Seizures
        6.1.5    Others
    6.2    North America Epilepsy Drugs Market (2017-2032) by Drug Generation
        6.2.1    Market Overview
        6.2.2    First Generation Drugs
        6.2.3    Second Generation Drugs
        6.2.4    Third Generation Drugs
    6.3    North America Epilepsy Drugs Market (2017-2032) by Age Group
        6.3.1    Market Overview
        6.3.2    Pediatric
        6.3.3    Adult
    6.4    North America Epilepsy Drugs Market (2017-2032) by Route of Administration
        6.4.1    Market Overview
        6.4.2    Oral
        6.4.3    Nasal
        6.4.4    Injectable 
        6.4.5    Rectal 
        6.4.6    Others
    6.5    North America Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        6.5.1    Market Overview
        6.5.2    Hospital Pharmacies
        6.5.3    Drug Stores and Retail Pharmacies
        6.5.4    Online Providers
    6.6    North America Epilepsy Drugs Market (2017-2032) by Countries
        6.6.1    Market Overview
        6.6.2    United States of America
        6.6.3    Canada
7    United States  of America Epilepsy Drugs Market (2017-2032)
    7.1    United States of America Epilepsy Drugs Market (2017-2032) by Seizure Type
        7.1.1    Market Overview
        7.1.2    Focal Seizures
        7.1.3    Generalized Seizures
        7.1.4    Non-epileptic Seizures
        7.1.5    Others
    7.2    United State of America Epilepsy Drugs Market (2017-2032) by Drug Generation
        7.2.1    Market Overview
        7.2.2    First Generation Drugs
        7.2.3    Second Generation Drugs
        7.2.4    Third Generation Drugs
    7.3    United State of America Epilepsy Drugs Market (2017-2032) by Age Group
        7.3.1    Market Overview
        7.3.2    Pediatric
        7.3.3    Adult
    7.4    United States of America Epilepsy Drugs Market (2017-2032) by Route of Administration
        7.4.1    Market Overview
        7.4.2    Oral
        7.4.3    Nasal
        7.4.4    Injectable 
        7.4.5    Rectal 
        7.4.6    Others
    7.5    United States of America Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        7.5.1    Market Overview
        7.5.2    Hospital Pharmacies
        7.5.3    Drug Stores and Retail Pharmacies
        7.5.4    Online Providers
8    Canada Epilepsy Drugs Market (2017-2032)
    8.1    Canada Epilepsy Drugs Market (2017-2032) by Seizure Type
        8.1.1    Market Overview
        8.1.2    Focal Seizures
        8.1.3    Generalized Seizures
        8.1.4    Non-epileptic Seizures
        8.1.5    Others
    8.2    Canada Epilepsy Drugs Market (2017-2032) by Drug Generation
        8.2.1    Market Overview
        8.2.2    First Generation Drugs
        8.2.3    Second Generation Drugs
        8.2.4    Third Generation Drugs
    8.3    Canada Epilepsy Drugs Market (2017-2032) by Age Group
        8.3.1    Market Overview
        8.3.2    Pediatric
        8.3.3    Adult
    8.4    Canada Epilepsy Drugs Market (2017-2032) by Route of Administration
        8.4.1    Market Overview
        8.4.2    Oral
        8.4.3    Nasal
        8.4.4    Injectable 
        8.4.5    Rectal 
        8.4.6    Others
    8.5    Canada Epilepsy Drugs Market (2017-2032) by Distribution Channel 
        8.5.1    Market Overview
        8.5.2    Hospital Pharmacies
        8.5.3    Drug Stores and Retail Pharmacies
        8.5.4    Online Providers
9    Regulatory Framework
10    Patent Analysis
    10.1     Analysis by Type of Patent
    10.2     Analysis by Publication year
    10.3     Analysis by Issuing Authority
    10.4     Analysis by Patent Age
    10.5     Analysis by CPC Analysis
    10.6     Analysis by Patent Valuation 
    10.7     Analysis by Key Players
11    Funding and Investment Analysis
    11.1     Analysis by Funding Instances
    11.2     Analysis by Type of Funding
    11.3     Analysis by Funding Amount
    11.4     Analysis by Leading Players
    11.5     Analysis by Leading Investors
    11.6     Analysis by Geography
12    Partnership and Collaborations Analysis
    12.1     Analysis by Partnership Instances
    12.2     Analysis by Type of Partnership
    12.3     Analysis by Leading Players
    12.4     Analysis by Geography
13    Supplier Landscape
    13.1    Market Share by Top 5 Companies
    13.2    UCB SA
        13.2.1    Financial Analysis
        13.2.2    Product Portfolio
        13.2.3    Demographic Reach and Achievements
        13.2.4    Mergers and Acquisitions
        13.2.5    Certifications 
    13.3    Novartis AG
        13.3.1    Financial Analysis
        13.3.2    Product Portfolio
        13.3.3    Demographic Reach and Achievements
        13.3.4    Mergers and Acquisitions
        13.3.5    Certifications
    13.4    Pfizer Inc.
        13.4.1    Financial Analysis
        13.4.2    Product Portfolio
        13.4.3    Demographic Reach and Achievements
        13.4.4    Mergers and Acquisitions
        13.4.5    Certifications
    13.5    GSK Plc
        13.5.1    Financial Analysis
        13.5.2    Product Portfolio
        13.5.3    Demographic Reach and Achievements
        13.5.4    Mergers and Acquisitions
        13.5.5    Certifications
    13.6    Abbott Laboratories
        13.6.1    Financial Analysis
        13.6.2    Product Portfolio
        13.6.3    Demographic Reach and Achievements
        13.6.4    Mergers and Acquisitions
        13.6.5    Certifications
    13.7    Sanofi SA
        13.7.1    Financial Analysis
        13.7.2    Product Portfolio
        13.7.3    Demographic Reach and Achievements
        13.7.4    Mergers and Acquisitions
        13.7.5    Certifications
    13.8    Sumitomo Pharma America Inc.
        13.8.1    Financial Analysis
        13.8.2    Product Portfolio
        13.8.3    Demographic Reach and Achievements
        13.8.4    Mergers and Acquisitions
        13.8.5    Certifications
    13.9    Teva Pharmaceutical Industries Ltd
        13.9.1    Financial Analysis
        13.9.2    Product Portfolio
        13.9.3    Demographic Reach and Achievements
        13.9.4    Mergers and Acquisitions
        13.9.5    Certifications
    13.10    Catalyst Pharmaceuticals Inc
        13.10.1    Financial Analysis
        13.10.2    Product Portfolio
        13.10.3    Demographic Reach and Achievements
        13.10.4    Mergers and Acquisitions
        13.10.5    Certifications
    13.11    Alkem Laboratories Ltd
        13.11.1    Financial Analysis
        13.11.2    Product Portfolio
        13.11.3    Demographic Reach and Achievements
        13.11.4    Mergers and Acquisitions
        13.11.5    Certifications
14    North America Epilepsy Drugs Market – Distribution Model (Additional Insight)
    14.1     Overview 
    14.2     Potential Distributors 
    14.3     Key Parameters for Distribution Partner Assessment 
15    Key Opinion Leaders (KOL) Insights (Additional Insight)
16    Company Competitiveness Analysis (Additional Insight)
    16.1     Very Small Companies
    16.2     Small Companies
    16.3     Mid-Sized Companies
    16.4     Large Companies
    16.5     Very Large Companies
17    Payment Methods (Additional Insight)
    17.1     Government Funded
    17.2     Private Insurance
    17.3     Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.